Compare
DBV Technologies S.A. vs Fate Therapeutics Inc vs Prime Medicine, Inc. vs CG Oncology, Inc.
| Latest fiscal year | DBV Technologies S.A. DBVT | Fate Therapeutics Inc FATE | Prime Medicine, Inc. PRME | CG Oncology, Inc. CGON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.64M | $6.65M | $4.63M | $4.04M |
| Revenue growth (YoY) | +35.8% | -51.2% | +55.3% | +254.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$146.95M | -$136.31M | -$201.14M | -$161.00M |
| EPS (Diluted) | -$1.05 | -$1.15 | -$1.35 | -$2.08 |
| Operating cash flow | -$121.18M | -$106.08M | -$162.56M | -$132.35M |
| Free cash flow | -$121.71M | -$112.04M | -$167.09M | -$132.48M |
| Cash & equivalents | $194.17M | $46.63M | $63.03M | $32.49M |
| Total assets | $233.72M | $318.94M | $342.73M | $791.59M |
| Total liabilities | $64.95M | n/a | $221.87M | $38.99M |
| Shareholders' equity | $168.77M | $207.18M | $120.87M | $752.60M |
| Return on year-end equity | -87.1% | -65.8% | -166.4% | -21.4% |
| Shares outstanding | n/a | 115.36M | 180.51M | 80.69M |
Revenue, most recent five fiscal years
| Fiscal year | DBV Technologies S.A. | Fate Therapeutics Inc | Prime Medicine, Inc. | CG Oncology, Inc. |
|---|---|---|---|---|
| Latest | $5.64M Ended 2025-12-31 | $6.65M Ended 2025-12-31 | $4.63M Ended 2025-12-31 | $4.04M Ended 2025-12-31 |
| 1 year earlier | $4.15M Ended 2024-12-31 | $13.63M Ended 2024-12-31 | $2.98M Ended 2024-12-31 | $1.14M Ended 2024-12-31 |
| 2 years earlier | $15.73M Ended 2023-12-31 | $63.53M Ended 2023-12-31 | $0 Ended 2023-12-31 | $204.0K Ended 2023-12-31 |
| 3 years earlier | $4.84M Ended 2022-12-31 | $96.30M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | $5.71M Ended 2021-12-31 | $55.85M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a |